
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="publisher-id">jbpneu</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">J. bras. pneumol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">GZYfdY6BDfMGKwrXQYxsZFd</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S1806-37132022000201100</article-id>
      <article-id pub-id-type="doi">10.36416/1806-3756/e20220072</article-id>
      <article-id pub-id-type="other">01100</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>CORRESPONDENCE</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>ELMO helmet for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU: aspects of/comments on its assembly and methodology</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-5259-1648</contrib-id>
          <name>
            <surname>Mazza</surname>
            <given-names>Mariano</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2523-9769</contrib-id>
          <name>
            <surname>Fiorentino</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0571-2050</contrib-id>
          <name>
            <surname>Esquinas</surname>
            <given-names>Antonio M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="original">. Unità Operativa Complessa di Pneumologia Semintensiva COVID, Azienda Ospedaliera Sant’Anna e San Sebastiano di Rilievo Nazionale e alta Specializzazione, Caserta, Italia.</institution>
        <institution content-type="orgdiv1">Unità Operativa Complessa di Pneumologia Semintensiva COVID</institution>
        <institution content-type="orgname">Azienda Ospedaliera Sant’Anna e San Sebastiano di Rilievo Nazionale e alta Specializzazione</institution>
        <addr-line>
          <city>Caserta</city>
        </addr-line>
        <country country="IT">Italia</country>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="original">. Unità Operativa Complessa di Fisiopatologia e Riabilitazione Respiratoria P.O. Monaldi, 1o Utsir Covid PO, Ospedale Cotugno, Azienda Ospedaliera dei Colli, Napoli, Italia.</institution>
        <institution content-type="orgdiv2">1o Utsir Covid PO</institution>
        <institution content-type="orgdiv1">Ospedale Cotugno</institution>
        <institution content-type="orgname">Azienda Ospedaliera dei Colli</institution>
        <addr-line>
          <city>Napoli</city>
        </addr-line>
        <country country="IT">Italia</country>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="original">. Intensive Care and Non Invasive Ventilatory Unit, Hospital General Universitario Jose M Morales Meseguer, Murcia, España.</institution>
        <institution content-type="orgdiv1">Intensive Care and Non Invasive Ventilatory Unit</institution>
        <institution content-type="orgname">Hospital General Universitario Jose M Morales Meseguer</institution>
        <addr-line>
          <city>Murcia</city>
        </addr-line>
        <country country="ES">España</country>
      </aff>
      <pub-date date-type="pub" publication-format="electronic">
        <day>13</day>
        <month>05</month>
        <year>2022</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2022</year>
      </pub-date>
      <volume>48</volume>
      <issue>02</issue>
      <elocation-id>e20220072</elocation-id>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>We have read with great interest the study by Tomaz et al.,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> which analyzes the clinical efficacy of a new model of a helmet-CPAP system, designated ELMOcpap, in COVID-19-related acute hypoxemic respiratory failure. We consider that that study published in the last issue of <italic>Jornal Brasileiro de Pneumologia</italic> represents a great advance regarding CPAP therapy, showing a new model of a helmet-CPAP device, and contributes to extend the use of such devices outside ICUs. However, we believe that there are some clinical and technical aspects that should be discussed.</p>
    <p>First, Table 1 <xref ref-type="bibr" rid="B1"><sup>1</sup></xref> shows that all patients were affected by alkalosis (pH &gt; 7.48) before starting therapy with the device, and the observed RR was not very high and not significantly different from that after its use (28.5 [24.5-34.0] vs. 26.5 [23.5-32.5] breaths/min; p = 0.866). We wonder if the authors considered the possibility of the presence of mixed alkalosis and if these data could be associated with successive helmet-CPAP setting adjustments. We think that this may also predispose patients to self-induced lung injury (P-SILI),<xref ref-type="bibr" rid="B2"><sup>2</sup></xref> and we recommend that future studies about ELMOcpap should evaluate, by means of bench or clinical trials, data regarding Vt measurements, ELMOcpap settings, and P-SILI prevention.<xref ref-type="bibr" rid="B3"><sup>3</sup></xref> </p>
    <p>Second, according to Figure 1 in that study,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> we observed that the authors have combined two humidification systems: an active humidifying jar system and a heat and moisture exchanger filter. We consider that this association could predispose to obstruction of the system by condensation, CPAP asynchrony, and, consequently, P-SILI,<xref ref-type="bibr" rid="B2"><sup>2</sup></xref> particularly in such patients. Referring to the fact that “None of the research team members or hospital staff acquired COVID-19 during the study,” it has not been stated in which way safety or diffusibility through the interface to prevent the spread of the virus was evaluated. Data about environmental air analysis would have been useful, so as to exclude that no one got infected only because the staff wore personal protective equipment and not because of interface security.</p>
    <p>Additionally, an important aspect for a future design could be the measurement of internal helmet gas volume, the use of antiviral filters both on the inspiratory and expiratory ports, and the implementation of an anti-suffocation valve.</p>
    <p>Lastly, we observed a great variability of total ELMOcpap therapy time, because the range of daily duration of the sessions was 60-1,230 min, and it is not clear whether defined criteria were established as a guideline, or whether the duration was dependent only on the patient; in addition, it is unclear whether other oxygen therapy options while ELMOcpap was not connected were applied. This is controversial if we consider the level of disease severity and gas exchange at admission showed in Table 2. <xref ref-type="bibr" rid="B1"><sup>1</sup></xref> We also wonder if the authors designed the ELMOcpap device for continuous noninvasive support application outside the ICU as well, considering that they conducted the study with patients with moderate to severe ARDS, which is evident in Figure 3,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> where we find values of Pa<sub>O2</sub>/Fi<sub>O2</sub> &lt; 150.</p>
    <p>Further clinical trials are needed to evaluate some methodological and technical aspects of this new helmet-CPAP system to be used outside ICUs.</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1 Tomaz BS, Gomes GC, Lino JA, Menezes DGA, Soares JB, Furtado V, et al. ELMO, a new helmet interface for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU: a feasibility study. J Bras Pneumol. 2022;48(1):e20210349. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36416/1806-3756/e20210349">https://doi.org/10.36416/1806-3756/e20210349</ext-link> </mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomaz</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Lino</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Menezes</surname>
              <given-names>DGA</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Furtado</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>ELMO, a new helmet interface for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU a feasibility study</article-title>
          <source>J Bras Pneumol</source>
          <year>2022</year>
          <volume>48</volume>
          <issue>1</issue>
          <elocation-id>e20210349</elocation-id>
          <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36416/1806-3756/e20210349">https://doi.org/10.36416/1806-3756/e20210349</ext-link>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2 Akoumianaki E, Vaporidi K, Georgopoulos D. The Injurious Effects of Elevated or Nonelevated Respiratory Rate during Mechanical Ventilation. Am J Respir Crit Care Med. 2019;199(2):149-157. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/rccm.201804-0726CI">https://doi.org/10.1164/rccm.201804-0726CI</ext-link> </mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akoumianaki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vaporidi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Georgopoulos</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>The Injurious Effects of Elevated or Nonelevated Respiratory Rate during Mechanical Ventilation</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2019</year>
          <volume>199</volume>
          <issue>2</issue>
          <fpage>149</fpage>
          <lpage>157</lpage>
          <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1164/rccm.201804-0726CI">https://doi.org/10.1164/rccm.201804-0726CI</ext-link>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3 Chiappero C, Misseri G, Mattei A, Ippolito M, Albera C, Pivetta E, Effectiveness and safety of a new helmet CPAP configuration allowing tidal volume monitoring in patients with COVID-19. Pulmonology. 2021;S2531-0437(21)00135-5. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pulmoe.2021.06.012">https://doi.org/10.1016/j.pulmoe.2021.06.012</ext-link> </mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiappero</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Misseri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mattei</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ippolito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Albera</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pivetta</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Effectiveness and safety of a new helmet CPAP configuration allowing tidal volume monitoring in patients with COVID-19</article-title>
          <source>Pulmonology</source>
          <year>2021</year>
          <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.pulmoe.2021.06.012">https://doi.org/10.1016/j.pulmoe.2021.06.012</ext-link>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="reply" id="s1" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Authors’ reply</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Authors’ reply</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2523-7296</contrib-id>
          <name>
            <surname>Tomaz</surname>
            <given-names>Betina Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff1n">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9342-7737</contrib-id>
          <name>
            <surname>Gomes</surname>
            <given-names>Gabriela Carvalho</given-names>
          </name>
          <xref ref-type="aff" rid="aff2n">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0968-4800</contrib-id>
          <name>
            <surname>Lino</surname>
            <given-names>Juliana Arcanjo</given-names>
          </name>
          <xref ref-type="aff" rid="aff2n">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-5546-5591</contrib-id>
          <name>
            <surname>Menezes</surname>
            <given-names>David Guabiraba Abitbol de</given-names>
          </name>
          <xref ref-type="aff" rid="aff2n">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2940-6309</contrib-id>
          <name>
            <surname>Soares</surname>
            <given-names>Jorge Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff2n">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-8721-4308</contrib-id>
          <name>
            <surname>Furtado</surname>
            <given-names>Vasco</given-names>
          </name>
          <xref ref-type="aff" rid="aff3n">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1555-049X</contrib-id>
          <name>
            <surname>Soares</surname>
            <given-names>Luiz</given-names>
            <suffix>Júnior</suffix>
          </name>
          <xref ref-type="aff" rid="aff1n">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-9597-3512</contrib-id>
          <name>
            <surname>Farias</surname>
            <given-names>Maria do Socorro Quintino</given-names>
          </name>
          <xref ref-type="aff" rid="aff4n">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-4575-3386</contrib-id>
          <name>
            <surname>Lima</surname>
            <given-names>Debora Lilian Nascimento</given-names>
          </name>
          <xref ref-type="aff" rid="aff4n">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-4414-3164</contrib-id>
          <name>
            <surname>Pereira</surname>
            <given-names>Eanes Delgado Barros</given-names>
          </name>
          <xref ref-type="aff" rid="aff1n">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-6002-0084</contrib-id>
          <name>
            <surname>Holanda</surname>
            <given-names>Marcelo Alcantara</given-names>
          </name>
          <xref ref-type="aff" rid="aff1n">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff5n">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1n">
        <label>1</label>
        <institution content-type="original">. Universidade Federal do Ceará - UFC - Fortaleza (CE) Brasil.</institution>
        <institution content-type="orgname">Universidade Federal do Ceará</institution>
        <addr-line>
          <city>Fortaleza</city>
          <state>CE</state>
        </addr-line>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff2n">
        <label>2</label>
        <institution content-type="original">. Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico - FUNCAP - Fortaleza (CE) Brasil.</institution>
        <institution content-type="orgname">Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico</institution>
        <addr-line>
          <city>Fortaleza</city>
          <state>CE</state>
        </addr-line>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff3n">
        <label>3</label>
        <institution content-type="original">. Universidade de Fortaleza - UNIFOR - Fortaleza (CE) Brasil.</institution>
        <institution content-type="orgname">Universidade de Fortaleza</institution>
        <addr-line>
          <city>Fortaleza</city>
          <state>CE</state>
        </addr-line>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff4n">
        <label>4</label>
        <institution content-type="original">. Hospital Estadual Leonardo da Vinci, Fortaleza (CE) Brasil.</institution>
        <institution content-type="orgname">Hospital Estadual Leonardo da Vinci</institution>
        <addr-line>
          <city>Fortaleza</city>
          <state>CE</state>
        </addr-line>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff5n">
        <label>5</label>
        <institution content-type="original">. Escola de Saúde Pública do Ceará Paulo Marcelo Martins Rodrigues, Fortaleza (CE) Brasil.</institution>
        <institution content-type="orgname">Escola de Saúde Pública do Ceará Paulo Marcelo Martins Rodrigues</institution>
        <addr-line>
          <city>Fortaleza</city>
          <state>CE</state>
        </addr-line>
        <country country="BR">Brasil</country>
      </aff>
    </front-stub>
    <body>
      <p>We thank the authors for their comments and questions regarding our study entitled “ELMO, a new helmet interface for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU: a feasibility study.”</p>
      <p>Concerning the first point mentioned by the authors, we agree with the observation regarding the coexistence of metabolic alkalosis in at least 8 of the 10 patients whose arterial blood gas analysis at admission, before the use of ELMO, showed base excess values above 2.0 mEq/L. A possible cause would be the pharmacological therapy with corticosteroids routinely used in patients before their inclusion in the study. Therefore, metabolic alkalosis is not related to the sequential application of CPAP with the helmet.</p>
      <p>The fact that some patients presented with hyperventilation in accordance with the respiratory alkalosis component is compatible with an increase in the respiratory drive, and, yes, that is possibly associated with an increase in transpulmonary pressure, a mechanism related to the occurrence of self-inflicted lung injury. In the absence of transpulmonary pressure measurement, we believe that Vt monitoring in devices such as the ELMO can identify those patients with a greater propensity to self-inflicted lung injury. The effects of the application of CPAP by helmet or another interface on Vt require investigation in clinical trials in the future, evaluating its relationship with the progression of lung injury or not. It is worth noting that, experimentally, the application of CPAP can attenuate the variation of transpulmonary pressure in ARDS.<xref ref-type="bibr" rid="B1n"><sup>1</sup></xref> </p>
      <p>Concerning the second point, it is worth explaining the following: first, the heat and moisture exchanger filter used in the ELMO inspiratory branch serves only as a “damper” for the noise generated by the high flow of gases and not for its primary function (heat/humidity); second, the gas passage through the unheated jar was just a practical resource to offer the mixture of gases without raising their temperature. We even observed that this fact prevented condensation inside the helmet and, in volunteers, it was associated with a better sensation of comfort during the use of ELMOcpap due to the slightly cooler temperature around the head and face.<xref ref-type="bibr" rid="B2n"><sup>2</sup></xref> Because the CPAP mechanism has a continuous flow of gases, there is no occurrence of asynchrony, unlike helmets coupled to mechanical ventilators, and current trigger mechanisms are not designed for this interface.</p>
      <p>The safety of the interface regarding the diffusibility of the virus was not the object of our study since it has already been reported in the literature<xref ref-type="bibr" rid="B3n"><sup>3</sup></xref>; the helmet interface has been considered safe and leakage is negligible when compared with face masks. The description of the absence of COVID-19 cases among researchers should not be seen as proof of this concept; however, we thought it best to report the data for recording purposes.</p>
      <p>We agree with the idea of continuing to improve the design of the ELMO helmet on several fronts, including the improvement of anti-suffocation mechanisms, the coupling of filters in the gas inlet and outlet, the optimization of its internal volume to reduce the predisposition to CO<sub>2</sub> rebreathing, the monitoring of respiratory variables, such as RR, Vt, and Fio<sub>2</sub>, as well as of intra-helmet pressure level, humidity, temperature, and others.</p>
      <p>Given the innovation of the characteristics of that study with this type of device, our group considered that the total time of therapy would be the maximum tolerated by the patient, and, in agreement with the medical team, we alternated it with the only oxygen therapy then available (reservoir mask), because a high-flow nasal cannula was not available. The degree of comfort observed was great, and the large-scale use after the feasibility study revealed cases of continuous use of ELMOcpap for periods as long as 12-24 h (unpublished data), which is in line with other reports in the literature.</p>
    </body>
    <back>
      <ref-list>
        <title>REFERENCES</title>
        <ref id="B1n">
          <label>1</label>
          <mixed-citation>1 Yoshida T, Grieco DL, Brochard L, Fujino Y. Patient self-inflicted lung injury and positive end-expiratory pressure for safe spontaneous breathing. Curr Opin Crit Care. 2020;26(1):59-65. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MCC.0000000000000691">https://doi.org/10.1097/MCC.0000000000000691</ext-link> </mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Brochard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fujino</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Patient self-inflicted lung injury and positive end-expiratory pressure for safe spontaneous breathing</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2020</year>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <lpage>65</lpage>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MCC.0000000000000691">https://doi.org/10.1097/MCC.0000000000000691</ext-link>
          </element-citation>
        </ref>
        <ref id="B2n">
          <label>2</label>
          <mixed-citation>2 Holanda MA, Tomaz BS, Menezes DGA, Lino JA, Gomes GC. ELMO 1.0: a helmet interface for CPAP and high-flow oxygen delivery. J Bras Pneumol. 2021;47(3):e20200590. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36416/1806-3756/e20200590">https://doi.org/10.36416/1806-3756/e20200590</ext-link>.</mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Holanda</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tomaz</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Menezes</surname>
                <given-names>DGA</given-names>
              </name>
              <name>
                <surname>Lino</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>ELMO 1 0: a helmet interface for CPAP and high-flow oxygen delivery</article-title>
            <source>J Bras Pneumol</source>
            <year>2021</year>
            <volume>47</volume>
            <issue>3</issue>
            <elocation-id>e20200590</elocation-id>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36416/1806-3756/e20200590">https://doi.org/10.36416/1806-3756/e20200590</ext-link>
          </element-citation>
        </ref>
        <ref id="B3n">
          <label>3</label>
          <mixed-citation>3 Ferioli M, Cisternino C, Leo V, Pisani L, Palange P, Nava S. Protecting healthcare workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev. 2020;29(155):200068. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1183/16000617.0068-2020">https://doi.org/10.1183/16000617.0068-2020</ext-link> </mixed-citation>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ferioli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cisternino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palange</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nava</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Protecting healthcare workers from SARS-CoV-2 infection practical indications</article-title>
            <source>Eur Respir Rev</source>
            <year>2020</year>
            <volume>29</volume>
            <issue>155</issue>
            <fpage>200068</fpage>
            <lpage>200068</lpage>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1183/16000617.0068-2020">https://doi.org/10.1183/16000617.0068-2020</ext-link>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </sub-article>
  <sub-article article-type="translation" id="s2" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>CORRESPONDÊNCIA</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Capacete ELMO para CPAP no tratamento da insuficiência respiratória aguda hipoxêmica por COVID-19 fora da UTI: aspectos/comentários sobre sua montagem e metodologia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-5259-1648</contrib-id>
          <name>
            <surname>Mazza</surname>
            <given-names>Mariano</given-names>
          </name>
          <xref ref-type="aff" rid="aff1s">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2523-9769</contrib-id>
          <name>
            <surname>Fiorentino</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref ref-type="aff" rid="aff2s">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0571-2050</contrib-id>
          <name>
            <surname>Esquinas</surname>
            <given-names>Antonio M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3s">
            <sup>3</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1s">
        <label>1</label>
        <institution content-type="original">. Unità Operativa Complessa di Pneumologia Semintensiva COVID, Azienda Ospedaliera Sant’Anna e San Sebastiano di Rilievo Nazionale e alta Specializzazione, Caserta, Italia.</institution>
      </aff>
      <aff id="aff2s">
        <label>2</label>
        <institution content-type="original">. Unità Operativa Complessa di Fisiopatologia e Riabilitazione Respiratoria P.O. Monaldi, 1o Utsir Covid PO, Ospedale Cotugno, Azienda Ospedaliera dei Colli, Napoli, Italia.</institution>
      </aff>
      <aff id="aff3s">
        <label>3</label>
        <institution content-type="original">. Intensive Care and Non Invasive Ventilatory Unit, Hospital General Universitario Jose M Morales Meseguer, Murcia, España.</institution>
      </aff>
    </front-stub>
    <body>
      <p>Lemos com grande interesse o estudo de Tomaz et al.,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> que analisa a eficácia clínica de um novo modelo de sistema de CPAP com capacete, denominado ELMOcpap, na insuficiência respiratória aguda hipoxêmica por COVID-19. Consideramos que esse estudo publicado no último número do Jornal Brasileiro de Pneumologia representa um grande avanço na terapia com CPAP, apresentando um novo modelo de dispositivo de CPAP com capacete, e contribui para a ampliação do uso de tais dispositivos fora das UTIs. No entanto, acreditamos que existem alguns aspectos clínicos e técnicos que devem ser discutidos.</p>
      <p>Em primeiro lugar, a Tabela 1 <xref ref-type="bibr" rid="B1"><sup>1</sup></xref> mostra que todos os pacientes já apresentavam alcalose (pH &gt; 7,48) antes de iniciar a terapia com o dispositivo, e a FR observada não foi muito alta nem significativamente diferente daquela observada após seu uso (28,5 [24,5-34,0] vs. 26,5 [23,5-32,5] ciclos/min; p = 0,866). Perguntamo-nos se os autores consideraram a possibilidade da presença de alcalose mista e se esses dados poderiam estar associados a sucessivos ajustes das configurações de CPAP com capacete. Achamos que isso também pode predispor os pacientes à <italic>self-induced lung injury</italic> (P-SILI, lesão pulmonar autoinduzida),<xref ref-type="bibr" rid="B2"><sup>2</sup></xref> e recomendamos que futuros estudos sobre o ELMOcpap avaliem, por meio de ensaios de bancada ou clínicos, dados sobre medidas de Vt, configurações de ELMOcpap, e a prevenção da P-SILI.<xref ref-type="bibr" rid="B3"><sup>3</sup></xref> </p>
      <p>Em segundo lugar, de acordo com a Figura 1 desse estudo,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> observamos que os autores combinaram dois sistemas de umidificação: um sistema de jarra umidificadora ativo e um filtro trocador de calor e umidade. Consideramos que essa associação poderia predispor à obstrução do sistema por condensação, assincronia de CPAP e, consequentemente, P-SILI,<xref ref-type="bibr" rid="B2"><sup>2</sup></xref><sup>)</sup> principalmente em tais pacientes. Quanto ao fato de que “Nenhum dos membros da equipe de pesquisa ou da equipe do hospital contraiu COVID-19 durante o estudo”, não foi mencionado de que forma foi avaliada a segurança ou difusibilidade através da interface para evitar a propagação do vírus. Dados sobre a análise do ar ambiente teriam sido úteis, de forma a excluir que ninguém se infectou apenas porque a equipe do hospital usava equipamentos de proteção individual e não por causa da segurança da interface.</p>
      <p>Além disso, um aspecto importante para um futuro projeto poderia ser a medida do volume de gás interno do capacete, o uso de filtros antivirais nos ramos inspiratório e expiratório e a implantação de uma válvula anti-asfixia.</p>
      <p>Por fim, observamos uma grande variabilidade do tempo total de terapia com o ELMOcpap, pois a variação da duração diária das sessões foi de 60-1.230 min, e não está claro se foram estabelecidos critérios definidos como diretriz, ou se a duração dependeu apenas do paciente; além disso, não está claro se foram aplicadas outras opções de oxigenoterapia enquanto o ELMOcpap não estava conectado. Isso é controverso se considerarmos o nível de gravidade da doença e as trocas gasosas na admissão mostrados na Tabela 2. Também nos perguntamos se os autores projetaram o dispositivo ELMOcpap para aplicação de suporte não invasivo contínuo também fora da UTI, considerando que eles realizaram o estudo com pacientes com SDRA moderada a grave, o que fica evidente na Figura 3,<xref ref-type="bibr" rid="B1"><sup>1</sup></xref> onde encontramos valores de Pa<sub>O2</sub>/Fi<sub>O2</sub> &lt; 150.</p>
      <p>Mais ensaios clínicos são necessários para avaliar alguns aspectos metodológicos e técnicos desse novo sistema de CPAP com capacete para uso fora da UTI.</p>
    </body>
    <sub-article article-type="reply" id="s3" xml:lang="pt">
      <front-stub>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Resposta dos autores</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Resposta dos autores</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-2523-7296</contrib-id>
            <name>
              <surname>Tomaz</surname>
              <given-names>Betina Santos</given-names>
            </name>
            <xref ref-type="aff" rid="aff1ns">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-9342-7737</contrib-id>
            <name>
              <surname>Gomes</surname>
              <given-names>Gabriela Carvalho</given-names>
            </name>
            <xref ref-type="aff" rid="aff2ns">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0003-0968-4800</contrib-id>
            <name>
              <surname>Lino</surname>
              <given-names>Juliana Arcanjo</given-names>
            </name>
            <xref ref-type="aff" rid="aff2ns">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0001-5546-5591</contrib-id>
            <name>
              <surname>Menezes</surname>
              <given-names>David Guabiraba Abitbol de</given-names>
            </name>
            <xref ref-type="aff" rid="aff2ns">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-2940-6309</contrib-id>
            <name>
              <surname>Soares</surname>
              <given-names>Jorge Barbosa</given-names>
            </name>
            <xref ref-type="aff" rid="aff2ns">
              <sup>2</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0001-8721-4308</contrib-id>
            <name>
              <surname>Furtado</surname>
              <given-names>Vasco</given-names>
            </name>
            <xref ref-type="aff" rid="aff3ns">
              <sup>3</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-1555-049X</contrib-id>
            <name>
              <surname>Soares</surname>
              <given-names>Luiz</given-names>
              <suffix>Júnior</suffix>
            </name>
            <xref ref-type="aff" rid="aff1ns">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-9597-3512</contrib-id>
            <name>
              <surname>Farias</surname>
              <given-names>Maria do Socorro Quintino</given-names>
            </name>
            <xref ref-type="aff" rid="aff4ns">
              <sup>4</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-4575-3386</contrib-id>
            <name>
              <surname>Lima</surname>
              <given-names>Debora Lilian Nascimento</given-names>
            </name>
            <xref ref-type="aff" rid="aff4ns">
              <sup>4</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-4414-3164</contrib-id>
            <name>
              <surname>Pereira</surname>
              <given-names>Eanes Delgado Barros</given-names>
            </name>
            <xref ref-type="aff" rid="aff1ns">
              <sup>1</sup>
            </xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid">0000-0002-6002-0084</contrib-id>
            <name>
              <surname>Holanda</surname>
              <given-names>Marcelo Alcantara</given-names>
            </name>
            <xref ref-type="aff" rid="aff1ns">
              <sup>1</sup>
            </xref>
            <xref ref-type="aff" rid="aff5ns">
              <sup>5</sup>
            </xref>
          </contrib>
        </contrib-group>
        <aff id="aff1ns">
          <label>1</label>
          <institution content-type="original">. Universidade Federal do Ceará - UFC - Fortaleza (CE) Brasil.</institution>
        </aff>
        <aff id="aff2ns">
          <label>2</label>
          <institution content-type="original">. Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico - FUNCAP - Fortaleza (CE) Brasil.</institution>
        </aff>
        <aff id="aff3ns">
          <label>3</label>
          <institution content-type="original">. Universidade de Fortaleza - UNIFOR - Fortaleza (CE) Brasil.</institution>
        </aff>
        <aff id="aff4ns">
          <label>4</label>
          <institution content-type="original">. Hospital Estadual Leonardo da Vinci, Fortaleza (CE) Brasil.</institution>
        </aff>
        <aff id="aff5ns">
          <label>5</label>
          <institution content-type="original">. Escola de Saúde Pública do Ceará Paulo Marcelo Martins Rodrigues, Fortaleza (CE) Brasil.</institution>
        </aff>
      </front-stub>
      <body>
        <p>Agradecemos aos autores os comentários e perguntas sobre nosso estudo intitulado “ELMO, uma nova interface do tipo capacete para CPAP no tratamento da insuficiência respiratória aguda hipoxêmica por COVID-19 fora da UTI: estudo de viabilidade”.</p>
        <p>No tocante ao primeiro ponto citado pelos autores, concordamos com a observação sobre a coexistência de alcalose metabólica em pelo menos 8 dos 10 pacientes cuja gasometria arterial na admissão, antes do uso do ELMO, mostrou valores de excesso de bases acima de 2,0 mEq/L. Uma possível causa seria a terapia farmacológica com corticosteroides utilizada rotineiramente nos pacientes antes de sua inclusão no estudo. Portanto, a alcalose metabólica não está relacionada à aplicação sequencial de CPAP com o capacete.</p>
        <p>O fato de alguns pacientes apresentarem hiperventilação segundo o componente alcalose respiratória é compatível com o aumento do <italic>drive</italic> respiratório, e, sim, isso possivelmente está associado ao aumento da pressão transpulmonar, mecanismo relacionado à ocorrência de lesão pulmonar autoinfligida. Na ausência da medição da pressão transpulmonar, acreditamos que a monitorização do Vt em aparelhos como o ELMO possa identificar aqueles pacientes com maior propensão à lesão pulmonar autoinfligida. Os efeitos da aplicação de CPAP por capacete ou outra interface no Vt requerem investigação em ensaios clínicos no futuro, avaliando sua relação com a progressão da lesão pulmonar ou não. Vale ressaltar que, experimentalmente, a aplicação de CPAP pode atenuar a variação da pressão transpulmonar na SDRA.<xref ref-type="bibr" rid="B1n"><sup>1</sup></xref> </p>
        <p>No tocante ao segundo ponto, vale esclarecer o seguinte: primeiro, o filtro trocador de calor e umidade utilizado no ramo inspiratório do ELMO serve apenas como “abafador” para o ruído gerado pelo alto fluxo de gases e não para sua função primária (calor/umidade); segundo, a passagem dos gases pela jarra não aquecida era apenas um recurso prático para oferecer a mistura de gases sem elevar sua temperatura. Observamos inclusive que esse fato impediu a condensação no interior do capacete e, em voluntários, esteve associado a uma maior sensação de conforto durante o uso do ELMOcpap em virtude da temperatura um pouco mais fria ao redor da cabeça e do rosto.<xref ref-type="bibr" rid="B2n"><sup>2</sup></xref> Como o mecanismo de CPAP tem um fluxo contínuo de gases, não há ocorrência de assincronia, diferentemente dos capacetes acoplados a ventiladores mecânicos, e os mecanismos de disparo atuais não são projetados para essa interface.</p>
        <p>A segurança da interface em relação à difusibilidade do vírus não foi objeto do nosso estudo, pois já foi relatada na literatura<xref ref-type="bibr" rid="B3n"><sup>3</sup></xref>; a interface do tipo capacete foi considerada segura e o vazamento é insignificante em comparação com as máscaras faciais. A descrição da ausência de casos de COVID-19 entre os pesquisadores não deve ser vista como prova desse conceito; no entanto, achamos melhor relatar os dados para fins de registro.</p>
        <p>Concordamos com a ideia de continuar a melhorar o desenho do capacete ELMO em várias frentes, incluindo a melhoria dos mecanismos antiasfixia, o acoplamento de filtros na entrada e saída de gases, a otimização do seu volume interno para reduzir a predisposição à reinalação de CO<sub>2</sub>, a monitorização de variáveis respiratórias, como FR, Vt e Fio<sub>2</sub>, bem como do nível de pressão, da umidade e da temperatura dentro do capacete, e outros.</p>
        <p>Dada a inovação das características do estudo com esse tipo de dispositivo, nosso grupo considerou que o tempo total de terapia seria o máximo tolerado pelo paciente, e, em acordo com a equipe médica, o alternamos com a única oxigenoterapia então disponível (máscara com reservatório), pois não havia disponibilidade de cânula nasal de alto fluxo. O grau de conforto observado foi grande, e o uso em larga escala após o estudo de viabilidade revelou casos de uso contínuo do ELMOcpap por períodos de até 12-24 h (dados não publicados), o que está de acordo com outros relatos na literatura.</p>
      </body>
    </sub-article>
  </sub-article>
</article>